150 related articles for article (PubMed ID: 8207207)
1. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases.
Komschlies KL; Gregorio TA; Gruys ME; Back TC; Faltynek CR; Wiltrout RH
J Immunol; 1994 Jun; 152(12):5776-84. PubMed ID: 8207207
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
3. Administration of IL-7 to normal mice stimulates B-lymphopoiesis and peripheral lymphadenopathy.
Morrissey PJ; Conlon P; Charrier K; Braddy S; Alpert A; Williams D; Namen AE; Mochizuki D
J Immunol; 1991 Jul; 147(2):561-8. PubMed ID: 1712810
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T
BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
7. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma.
Younes E; Haas GP; Dezso B; Ali E; Maughan RL; Kukuruga MA; Montecillo E; Pontes JE; Hillman GG
Cell Immunol; 1995 Oct; 165(2):243-51. PubMed ID: 7553889
[TBL] [Abstract][Full Text] [Related]
8. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
[TBL] [Abstract][Full Text] [Related]
9. Administration of human recombinant IL-7 to normal and irradiated mice increases the numbers of lymphocytes and some immature cells of the myeloid lineage.
Faltynek CR; Wang S; Miller D; Young E; Tiberio L; Kross K; Kelley M; Kloszewski E
J Immunol; 1992 Aug; 149(4):1276-82. PubMed ID: 1500718
[TBL] [Abstract][Full Text] [Related]
10. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-1 stimulation of lymphopoiesis.
Clark R; Strasser J; McCabe S; Robbins K; Jardieu P
J Clin Invest; 1993 Aug; 92(2):540-8. PubMed ID: 8349796
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
13. Early production of IL-4 and induction of Th2 responses in the lymph node originate from an MHC class I-independent CD4+NK1.1- T cell population.
von der Weid T; Beebe AM; Roopenian DC; Coffman RL
J Immunol; 1996 Nov; 157(10):4421-7. PubMed ID: 8906817
[TBL] [Abstract][Full Text] [Related]
14. Trafficking of 'immune' CD4(+)/CD8(+)T-lymphocytes into the RENCA tumour microcirculation in vivo in mice.
Ali SA; Rees RC; Anderson DQ; Reed MW; Goepel JR; Brown NJ
Br J Cancer; 2000 Oct; 83(8):1061-8. PubMed ID: 10993655
[TBL] [Abstract][Full Text] [Related]
15. Curative and protective effects of IL-10 in experimental autoimmune thyroiditis (EAT). Evidence for IL-10-enhanced cell death in EAT.
Mignon-Godefroy K; Rott O; Brazillet MP; Charreire J
J Immunol; 1995 Jun; 154(12):6634-43. PubMed ID: 7759896
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
17. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.
Melchionda F; Fry TJ; Milliron MJ; McKirdy MA; Tagaya Y; Mackall CL
J Clin Invest; 2005 May; 115(5):1177-87. PubMed ID: 15841203
[TBL] [Abstract][Full Text] [Related]
19. Regional oral tolerance in transgenic 2C mice.
Margenthaler JA; Flye MW
Surgery; 2005 Aug; 138(2):141-9. PubMed ID: 16153420
[TBL] [Abstract][Full Text] [Related]
20. Recombinant murine IL-3 fails to stimulate T or B lymphopoiesis in vivo, but enhances immune responses to T cell-dependent antigens.
Kimoto M; Kindler V; Higaki M; Ody C; Izui S; Vassalli P
J Immunol; 1988 Mar; 140(6):1889-94. PubMed ID: 3257991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
